You may leave me a review on these links:

Ongoing clinical trials

We’re dedicated to breaking boundaries through clinical studies and to finding new and improved ways to treat cancer that deliver better life outcomes for our patients

Ongoing clinical trials 62 clinical trials

Cancer

SEAMARK – C4221022

Colorectal Cancer

A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAFV600E-MUTANT, MSI-H/DMMR METASTATIC COL

Ongoing 2022

Cancer

AMGEN 20190172

Colorectal cancer

Ongoing 2022

Cancer

AMGEN 20190135

Basket – Solid Tumours

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumours With KRAS p.G12C Mutation

Ongoing 2022

Cancer

CONTACT-02

Prostate cancer

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Pro

Ongoing 2022

Cancer

RADIANT

Prostate cancer

Ongoing 2022

Cancer

KRYSTAL-12

Lung Cancer

Ongoing 2022

Cancer

DESTINY-12

Breast cancer

Ongoing 2022

Cancer

Prostact-Select

Prostate cancer

Ongoing 2022

Cancer

Oncobeta EPIC-SKIN (OB-RHSCT-101)

Therapeutic Group: Non-Melanoma Skin Cancer

Ongoing 2022

Cancer

SYS-CAPLIOX (AV-LIVPIBII-01)

Liver cancer

The aim of this study is to assess the efficacy of delivering chemotherapy treatment through the arteries directly to the liver, bypassing the main blood supply throughout the body.

Ongoing 2022

Cancer

HER2 REAL (D9673R00005)

Breast Cancer

Ongoing 2022

Cancer

ICP-CL-003030

Basket – Solid Tumours

Ongoing 2022

Cancer

SAMETA (D5086C00001)

Kidney (Genitourinary) Cancer

Ongoing 2022

Cancer

RO-CARDIAC

Cardio-Oncology

Ongoing 2022

Cancer

DECREASE

Prostate cancer

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA.

Ongoing 2022

Heart Disease

Vantage IDE (Enrolment opening soon)

Cardiovascular Disease

To evaluate the efficacy and safety of a new valve in patients with severe, symptomatic aortic stenosis.

Ongoing 2022

Heart Disease

Arrowhead (Enrolment opening soon)

Cardiovascular Disease

To evaluate the efficacy and safety on a new drug in participants with Mixed Dyslipidaemia.

Ongoing 2022

Heart Disease

AngelMed (Enrolment opening soon)

Cardiovascular Disease

To evaluate a new device in patients with prior acute coronary syndrome.

Ongoing 2022

Heart Disease

ZEUS

Cardiovascular Disease

To evaluate if treatment with a new drug reduces the risk cardiovascular disease in patients with established cardiovascular disease, chronic kidney disease and inflammation.

Ongoing 2022

Heart Disease

HighFLO

Heart Failure

To evaluate a new mitral valve replacement in patients who moderate-severe or severe mitral regurgitation at a high surgical risk.

Ongoing 2022

Heart Disease

IONIS

Cardiovascular Disease

To evaluate a new medication for the treatment of patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM).

Ongoing 2022

Heart Disease

FINEARTS-HF

Heart Failure

To evaluate the efficacy and safety of a new drug on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF ≥40%).

Ongoing 2022

Heart Disease

Cardialen AF CL008

Irregular Heart Beat

Clinical trial of patients with AF and their acceptability of MultiPulse Therapy (low voltage energy used to terminate tachyarrhythmias) prior to their clinically indicated electrophysiology procedure

Ongoing 2022

Heart Disease

CATALYST

Atrial Fibrillation

Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants.

Ongoing 2021

Cancer

AUS-PREDICT

Breast cancer

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy.

Ongoing 2021

Cancer

Checkmate-078

Bladder cancer

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC.

Ongoing 2021

Cancer

EVOLVE

Non-melanoma Skin Cancer

Evaluation of Oedema and lymphatic function following volumetric modulated arc therapy for non-melanoma extensive skin field cancerisation of the lower limbs.

Ongoing 2021

Cancer

PROPELLER

Prostate cancer

The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.

Ongoing 2021

Cancer

PRIMORDIUM

Prostate cancer

The hypothesis of study is addition of apalutamide to RT+ LHRHa provides superior efficacy in terms of PSMA-PET metastatic progression-free survival-ppMPFS.

Ongoing 2021

Cancer

MASTERPLAN

Pancreatic cancer

This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.

Ongoing 2021

Cancer

CUPID

Prostate cancer

This study will consist of four groups with the initial three groups undergoing dose escalation and the fourth group will be to confirm the optimal dose and imaging conditions.

Ongoing 2021

Cancer

CONCERTO

Breast cancer

A comparison of two routinely used skin treatments for women with breast cancer undergoing radiation therapy.

Ongoing 2021

Cancer

Telix ENHANCING

Prostate cancer

The purpose of this study is to determine the effect of androgen deprivation therapy, a treatment commonly prescribed in prostate cancer patients, on the effectiveness of medical imaging techniques.

Ongoing 2021

Cancer

NINJA

Prostate cancer

The NINJA clinical trial aims to compare two emerging schedules of radiotherapy in the treatment of prostate cancer.

Ongoing 2021

Cancer

GENTLER

Skin cancer

The purpose of this trial is to see if a reduced radiotherapy can deliver equivalent treatment response to full dose radiotherapy for patients with skin cancer.

Ongoing 2021

Cancer

CPOST

Skin cancer

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma.

Ongoing 2021

Cancer

BFSCT

Skin cancer

This study aims to clinically validate use of the Baker Skin Field Cancerisation Tool (BSFCT) in people attending St Vincent’s Hospital Melbourne dermatology clinic.

Ongoing 2021

Cancer

AVATAR

Breast Cancer

Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR).

Ongoing 2021

Cancer

ADAPT-MRL

Any cancer

A Long-Term, Prospective and Retrospective, Observational Registry Assessing Technical Data and Clinical Outcomes Following Treatment with MR-Linac.

Ongoing 2021

Cancer

CUPisco

Rare Tumours

Phase II targeted therapy or immunotherapy guided by genomic profiling versus platinum based chemotherapy (3C) (after receiving three cycles of platinum based chemotherapy).

Ongoing 2021

Cancer

DESTINY-Breast05

Breast cancer

This study will examine the efficacy and safety of trastuzumab deruxtecan compared with trastuzumab emtansine in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.

Ongoing 2021

Cancer

KEYPAD

Metastatic Kidney Cancer

This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).

Ongoing 2021

Cancer

BCG + MMC

Bladder Cancer

Adding mitomycin C to BCF as adjuvant intravesical therapy for high-risk, non muscle invasive bladder cancer, a randomised phase 3 trial.

Ongoing 2021

Cancer

KEYNOTE-992

Bladder cancer

Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).

Ongoing 2021

Cancer

CHALLENGE

Bowel cancer

A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High-Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial

Ongoing 2021

Cancer

DYNAMIC-III

Bowel Cancer

The aim of this study is to compare treatment informed by ctDNA results to standard care in patients with stage III colon cancer.

Ongoing 2021

Cancer

DREAM3R

Mesothelioma

The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.

Ongoing 2021

Cancer

B8011011

Carcinoma, Non-Small-Cell Lung

A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC).

Ongoing 2021

Cancer

AdvanTIG – BGB-A317-A1217-302

Non-small Cell Lung Cancer

The purpose of the study is to compare progression-free survival between Arm A and Arm B as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1.

Ongoing 2021

Cancer

MERMAID-2

Carcinoma, Non- Small Cell Lung

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

Ongoing 2021

Cancer

MERMAID-1

Carcinoma, Non-Small-Cell Lung

The purpose of this study is to assess the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

Ongoing 2021

Cancer

DASL-HiCaP

Prostate Cancer

The purpose of this study is to see if a new drug, darolutamide, combined with the current best treatments, can improve outcomes for people with prostate cancer.

Ongoing 2021

Cancer

ARANOTE

Prostate cancer

This study will assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

Ongoing 2021

Cancer

ENZA-p

Prostate Cancer

Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.

Ongoing 2020

Heart Disease

Cardialen AF CL007

Atrial Fibrillation

Clinical trial of patients with AF and their acceptability of MultiPulse Therapy (low voltage energy used to terminate tachyarrhythmias) prior to their clinically indicated electrophysiology procedure

Ongoing 2020

Heart Disease

VFAHF

Heart Failure

To collect data and evaluate the safety of Cardiac Resynchronisation Therapy (CRT) by utilising new techniques and investigational systems for patients in heart failure.

Ongoing 2020

Benign Conditions

DEPART

Connective Tissue Disorders

GenesisCare is recruiting patients with Dupuytren’s Disease for a research study called ‘DEPART’.

Ongoing 2020 Multiple Locations

Heart Disease

PORTICO-NG

Aortic Valve Stenosis

To evaluate a new valve, the Portico™ NG Transcatheter Aortic Heart Valve, in patients who have symptomatic, severe aortic stenosis and are determined to be at high or extreme surgical risk.

Ongoing 2019

Heart Disease

HighLife

Heart Failure due to mitral valve regurgitation

To evaluate a new valve in patients with moderate-severe or severe mitral regurgitation and at high surgical risk.

Ongoing 2019

Cancer

EXPERT

Early Breast Cancer

A unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.

Ongoing 2019

Heart Disease

SUCCOUR MRI SUB-STUDY

Cardio-Oncology

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy.

Ongoing 2019

Cancer

NDROR

Skin registry

To collect data to evaluate specified outcomes for patients undergoing radiotherapy for skin cancer and inflammatory skin conditions.

Ongoing 2019

No Results